Changes in circulating lipids level over time after acquiring HCV infection: results from ERCHIVES

BMC Infectious Diseases

Research Article

Abdul-Badi Abou-Samra¹  Tracey G. Simon²  Raymond T. Chung²  Peng Yan³  Adeel A. Butt⁴ 

[1] Hamad Medical Corporation, Doha, Qatar;Massachusetts General Hospital, Boston, MA, USA;VA Pittsburgh Healthcare System, 3601 Fifth Avenue, Suite 3A, 15213, Pittsburgh, PA, USA;VA Pittsburgh Healthcare System, 3601 Fifth Avenue, Suite 3A, 15213, Pittsburgh, PA, USA;University of Pittsburgh School of Medicine, Pittsburgh, PA, USA;Hamad Healthcare Quality Institute, Doha, Qatar;Hamad Medical Corporation, Doha, Qatar;

关键词: HCV;    Lipid;    Cholesterol;    LDL;    ERCHIVES;    Seroconversion;   

DOI  :  10.1186/s12879-015-1268-2

 received in 2015-07-07, accepted in 2015-11-05,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundChanges in lipid levels over time after acquiring HCV infection, and how they differ from HCV-uninfected persons are unknown.MethodsWe used ERCHIVES to identify those with a known HCV seroconversion window and persistently negative controls. We excluded subjects with HIV and hepatitis B and those who received lipid lowering agents. Total Cholesterol (TC), low-density lipoproteins (LDL), high-density lipoproteins (HDL), triglycerides (TG) and non-HDL cholesterol were retrieved at yearly intervals and plotted over time.ResultsAmong 1,270 HCV+ and 5,070 HCV- subjects, median age [IQR] was 47[37,53] for HCV+ and 52[47,57] for the HCV- group; 69 % were White and 91 % were males in each group. Mean BMI [SD] was 26.94[6.73] in the HCV+ and 28.15 [5.98] in the HCV- group (P < 0.001). Over a 10-year follow-up period among HCV+ persons, TC decreased by (mean (SD) mg/dL) 12.06(36.95), LDL by 9.22(31.44), TG by 13.58(87.01) and non-HDL-C by 12.55(35.14). Among HCV- persons, TC cholesterol decreased by 4.15(31.21), LDL by 4.16(26.51); TG by 4.42(82.34) and non-HDL-C by 5.78(30.17).ConclusionsAfter HCV acquisition, TC, LDL, TG and non-HDL-C progressively decline over time independent of BMI and liver fibrosis. Consequences of lipid changes and the need and optimal timing of lipid lowering therapy in HCV+ persons require further study.

【 授权许可】

CC BY   
© Butt et al. 2015